Moreover, 14 approved drugs are listed in the “GPCRdb drug-target classification tree” for the H2R, of which some are “blockbuster” drugs for the treatment of peptic ulcer and gastroesophageal reflux disease by antagonizing H2R-mediated gastric acid secretion in response to histamine [6]. Here, HRH2 is linked to gastroesophageal reflux disease.